Ticker

New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference call later in April 2026 to review new biomarker signature Biomarker signature meets pharmacodynamic/response criteria established by FDA's Biomarkers, EndpointS and other Tools (BEST) program for use as a surrogate…

Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human health Will assist with listeria oncology pipeline prioritization, combinations with other oncology-focused biotechnologies and tADC candidate selection for further development New York, New York--(Newsfile Corp. - April 13, 2026) - OS Therapies,…

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of OS Therapies Incorporated (NYSE American: OSTX) resulting from allegations that OS Therapies may have issued materially misleading business information to the investing public. So what: If you purchased OS Therapies securities you may be entitled to…

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of OS Therapies Incorporated (NYSE American: OSTX) resulting from allegations that OS Therapies may have issued materially misleading business information to the investing public. So what: If you purchased OS Therapies securities you may be entitled to…

Senior leadership roles at Guardant Health, Genentech and Pfizer Regulatory, clinical and commercial expertise in therapeutics and biomarkers Will assist with osteosarcoma regulatory advice and oncology pipeline prioritization New York, New York--(Newsfile Corp. - April 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer…